• M.D. National Yang-Ming University School of Medicine
• Ph.D. National Yang-Ming University, Institute of Clinical Medicine
  Post-doctor fellowship Vanderbilt University USAInstitute of Clinical Medicine, National Yang-Ming University

• Director, General Clinical Research Center (GCRC), Taipei Veterans General Hospital
• Director, Heart Failure Center, Taipei Veterans General Hospital
• Professor of Medicine, National Yang Ming Chiao Tung University
• Attending Physician, Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital

• Professor of Medicine, National Yang Ming Chiao Tung University

• Chairman of the 2010, 2015 and 2017 HT Guidelines of Taiwan Society of Cardiology/Taiwan Hypertension Society
• Co-Chairman of the 2022 HT Guidelines of Taiwan Society of Cardiology/Taiwan Hypertension Society
• Chairman of the 2016 AF Guidelines of Taiwan Society of Cardiology/Taiwan Heart Rhythm Society.
• Chairperson of the 2017 Consensus of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation
• Chairman of the 2018 Consensus of Taiwan Society of Cardiology and Diabetes Association of Republic of China (Taiwan) on the Management of Patients with Type 2 Diabetes and Cardiovascular Diseases
• Chairman of the 2020 Consensus of Taiwan Society of Cardiology on the Pharmacological Management of Patients with Type 2 Diabetes and Cardiovascular Diseases
• Chairman of the 2021 Consensus Pathway of the Taiwan Society of Cardiology on Novel Therapy for Type 2 Diabetes
• Chairman of the 2022 Stroke Prevention in Atrial Fibrillation: Consensus Statement of JACC: Asia (Part 1 &2)
• Chairman of the 2023 Consensus of Taiwan Society of Cardiology on the Pharmacological Treatment of Chronic Heart Failure
• Co-Chairman of the 2023 Guidelines of the Taiwan Society of Cardiology on the Diagnosis and Management of Chronic Coronary Syndrome
• Since 2006, Chiang has given more than 3,000 lectures in domestic and international symposia and meetings.
• ACS, HERMES, VICTORION-1 PREVENT)
• Steering Committee for 23 trials (AMISH, COSIMA 2, CEPHEUS, SIGNIFY, REALISEAF, SAVOR-TIMI53, ACCELERATE, DECLARE-TIMI 58, ODYSSEY, THEMIS, STRENGTH, ROSTAFUROXIN HT trial, VICTORIA,DAPA-HF, SCORED, DELIVER, FINEARTS-HF, Lp(a)HORIZON, ORION-18, ZEUS, OCEANIC-AF, HERMES)

• Clinical trials, Clinical Pharmacology
• Cardiology
• Cardiac Electrophysiology
• Arrhythmia
• Editorial Board: Circulation, JACC-Heart Failure, JACC-Asia (Associated editor), Current Hypertension Report, Journal of Chinese Medical Association, Journal of Arrhythmia, International Journal of Arrhythmia, Journal of Asian Pacific Society of Cardiology
• National Lead Investigator for 53 trials (AMISH, AVE/7688 [II], CRESCENDO, YM150 [II], COSIMA 2, LCZ696 [II], RECOVER 2, CEPHEUS, ENGAGE-TIMI 48, SIGNIFY, REALISEAF, T-EMERGE, SAVOR-TIMI 53, LAVENDER, ARTEMIS, ELIXA, Dronedarone PK, TAK-875 304, TAK-875 306, TAK-875 307, ACCELERATE, DECLARE-TIMI 58, ODYSSEY CVOT, CEPHEUS-5S, THEMIS, EINSTEIN CHOICE, GARFIELD-VTE, STRENGTH, ODYSSEY-KT, HARMONY, VICTORIA, ENTRUST, DAPA-HF, BET-MACE, SCORED, DELIVER, SURPASS-CVOT, FINEARTS-HF, Lp(a) HORIZON, MIRACLE, SUMMIT, ENDEAVOR, ORION-18, ZEUS, VICTOR, VICTORION-2 PREVENT, OCEANIC-AF, SURMONT-MMO, LIBREXIA-AF, LIBREXIA-ACS, HERMES, VICTORION-1 PREVENT)
• Steering Committee for 23 trials (AMISH, COSIMA 2, CEPHEUS, SIGNIFY, REALISEAF, SAVOR-TIMI53, ACCELERATE, DECLARE-TIMI 58, ODYSSEY, THEMIS, STRENGTH, ROSTAFUROXIN HT trial, VICTORIA,DAPA-HF, SCORED, DELIVER, FINEARTS-HF, Lp(a)HORIZON, ORION-18, ZEUS, OCEANIC-AF, HERMES)

• Arrhythmia
• Hypertension
• Hyperlipidemia
• Clinical trials
• Editorial Board: Circulation, JACC-Heart Failure, Current Hypertension Report, Journal of Chinese Medical Association, Journal of Arrhythmia, International Journal of Arrhythmia
• National Lead Investigator for 40 trials (AMISH, AVE/7688 [II], CRESCENDO, YM150 [II], COSIMA 2, LCZ696 [II], RECOVER 2, CEPHEUS, ENGAGE-TIMI 48, SIGNIFY, REALISEAF, T-EMERGE, SAVOR-TIMI 53, LAVENDER, ARTEMIS, ELIXA, Dronedarone PK, TAK-875 304, TAK-875 306, TAK-875 307, ACCELERATE, DECLARE-TIMI 58, ODYSSEY CVOT, CEPHEUS-5S, THEMIS, EINSTEIN CHOICE, GARFIELD-VTE, STRENGTH, ODYSSEY-KT, HARMONY, VICTORIA,ENTRUST, DAPA-HF, BET-MACE, SCORED, DELIVER, SURPASS-CVOT, FINEARTS-HF, Lp(a)HORIZON, MIRACLE)
• Steering Committee for 17 trials (AMISH, COSIMA 2, CEPHEUS, SIGNIFY, REALISEAF, SAVOR-TIMI53, ACCELERATE, DECLARE-TIMI58, ODYSSEY, THEMIS, STRENGTH, ROSTAFUROXIN HT trial, VICTORIA, DAPA-HF, SCORED, DELIVER, FINEARTS-HF)
•  Chairman of the 2010, 2015 and 2017 HT Guidelines of Taiwan Society of Cardiology/Taiwan Hypertension Society
• Chairman of the 2016 AF Guidelines of Taiwan Society of Cardiology/Taiwan Heart Rhythm Society.
• Chairperson of 2017 Consensus of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation
• Chairman of the 2018 Consensus of Taiwan Society of Cardiology and Diabetes Association of Republic of China (Taiwan) on the Management of Patients with Type 2 Diabetes and Cardiovascular Diseases
• Chairman of the 2020 Consensus of Taiwan Society of Cardiology on the Pharmacological Management of Patients with Type 2 Diabetes and Cardiovascular Diseases
• Since 2006, Chiang has given more than 3,000 lectures in domestic and international symposia and meetings.

• cechiang@vghtpe.gov.tw

1. Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Martinez F, Shah SJ, Desai AS, Jhund PS, Belohlavek J, Chiang CE, Borleffs CJW, Comin-Colet J, Dobreanu D, Drozdz J, Fang JC, Alcocer-Gamba MA, Al Habeeb W, Han Y, Cabrera Honorio JW, Janssens SP, Katova T, Kitakaze M, Merkely B, O'Meara E, Saraiva JFK, Tereshchenko SN, Thierer J, Vaduganathan M, Vardeny O, Verma S, Pham VN, Wilderäng U, Zaozerska N, Bachus E, Lindholm D, Petersson M, Langkilde AM; DELIVER Trial Committees and Investigators. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med. 2022 Sep 22;387(12):1089-1098.
2. McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Bělohlávek J, Böhm M, Chiang CE, Chopra VK, de Boer RA, Desai AS, Diez M, Drozdz J, Dukát A, Ge J, Howlett JG, Katova T, Kitakaze M, Ljungman CEA, Merkely B, Nicolau JC, O'Meara E, Petrie MC, Vinh PN, Schou M, Tereshchenko S, Verma S, Held C, DeMets DL, Docherty KF, Jhund PS, Bengtsson O, Sjöstrand M, Langkilde AM; DAPA-HF Trial Committees and Investigators. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019 Nov 21;381(21):1995-2008.
3. Vardeny O, Fang JC, Desai AS, Jhund PS, Claggett B, Vaduganathan M, de Boer RA, Hernandez AF, Lam CSP, Inzucchi SE, Martinez FA, Kosiborod MN, DeMets D, O'Meara E, Zieroth S, Comin-Colet J, Drozdz J, Chiang CE, Kitakaze M, Petersson M, Lindholm D, Langkilde AM, McMurray JJV, Solomon SD. Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial. Nat Med. 2022 ;28(12):2504-2511.
4. Butt JH, Jhund PS, Belohlávek J, de Boer RA, Chiang CE, Desai AS, Drożdż J, Hernandez AF, Inzucchi SE, Katova T, Kitakaze M, Kosiborod MN, Lam CSP, Maria Langkilde A, Lindholm D, Bachus E, Martinez F, Merkely B, Petersson M, Saraiva JFK, Shah SJ, Vaduganathan M, Vardeny O, Wilderäng U, Claggett BC, Solomon SD, McMurray JJV. Efficacy and Safety of Dapagliflozin According to Frailty in Patients With Heart Failure: A Prespecified Analysis of the DELIVER Trial. Circulation. 2022 ;146(16):1210-1224.
5. Petrie MC, Verma S, Docherty KF, Inzucchi SE, Anand I, Belohlávek J, Böhm M, Chiang CE, Chopra VK, de Boer RA, Desai AS, Diez M, Drozdz J, Dukát A, Ge J, Howlett J, Katova T, Kitakaze M, Ljungman CEA, Merkely B, Nicolau JC, O'Meara E, Vinh PN, Schou M, Tereshchenko S, Køber L, Kosiborod MN, Langkilde AM, Martinez FA, Ponikowski P, Sabatine MS, Sjöstrand M, Solomon SD, Johanson P, Greasley PJ, Boulton D, Bengtsson O, Jhund PS, McMurray JJV. Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes. JAMA. 2020 ;323(14):1353-1368.
6. White HD, Schwartz GG, Szarek M, Bhatt DL, Bittner VA, Chiang CE, Diaz R, Goodman SG, Jukema JW, Loy M, Pagidipati N, Pordy R, Ristić AD, Zeiher AM, Wojdyla DM, Steg PG; ODYSSEY OUTCOMES Investigators. Alirocumab after acute coronary syndrome in patients with a history of heart failure. Eur Heart J. 2022 ;43(16):1554-1565.
7. Butt JH, Dewan P, Merkely B, Belohlávek J, Drożdż J, Kitakaze M, Inzucchi SE, Kosiborod MN, Martinez FA, Tereshchenko S, Ponikowski P, Bengtsson O, Lindholm D, Langkilde AM, Schou M, Sjöstrand M, Solomon SD, Sabatine MS, Chiang CE, Docherty KF, Jhund PS, Køber L, McMurray JJV. Efficacy and Safety of Dapagliflozin According to Frailty in Heart Failure With Reduced Ejection Fraction : A Post Hoc Analysis of the DAPA-HF Trial. Ann Intern Med. 2022 Jun;175(6):820-830.
8. Solomon SD, Vaduganathan M, Claggett BL, de Boer RA, DeMets D, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Martinez F, Shah SJ, Belohlavek J, Chiang CE, Willem Borleffs CJ, Comin-Colet J, Dobreanu D, Drozdz J, Fang JC, Alcocer Gamba MA, Al Habeeb W, Han Y, Cabrera Honorio JW, Janssens SP, Katova T, Kitakaze M, Merkely B, O'Meara E, Kerr Saraiva JF, Tereschenko SN, Thierer J, Vardeny O, Verma S, Vinh PN, Wilderäng U, Zaozerska N, Lindholm D, Petersson M, McMurray JJV. Baseline Characteristics of Patients With HF With Mildly Reduced and Preserved Ejection Fraction: DELIVER Trial. JACC Heart Fail. 2022 ;10(3):184-197.
9. Jhund PS, Ponikowski P, Docherty KF, Gasparyan SB, Böhm M, Chiang CE, Desai AS, Howlett J, Kitakaze M, Petrie MC, Verma S, Bengtsson O, Langkilde AM, Sjöstrand M, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Sabatine MS, Solomon SD, McMurray JJV. Dapagliflozin and Recurrent Heart Failure Hospitalizations in Heart Failure With Reduced Ejection Fraction: An Analysis of DAPA-HF. Circulation. 202118;143(20):1962-1972.
10. Inzucchi SE, Docherty KF, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Solomon SD, Verma S, Bělohlávek J, Böhm M, Chiang CE, de Boer RA, Diez M, Dukát A, Ljungman CEA, Bengtsson O, Langkilde AM, Sjöstrand M, Jhund PS, McMurray JJV; DAPA-HF Investigators and Committees. Dapagliflozin and the Incidence of Type 2 Diabetes in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis From DAPA-HF. Diabetes Care. 2021 ;44(2):586-594.

限於篇幅,以上謹為代表著作